Genotyping Natural Killer Immune Checkpoints to Discover Biomarkers of Response

Clin Cancer Res. 2018 Jan 1;24(1):3-5. doi: 10.1158/1078-0432.CCR-17-2884. Epub 2017 Nov 9.

Abstract

Immune checkpoints have been a focus of immunotherapy in the recent decade. Killer cell immunoglobulin-like receptors (KIR) and their cognate human leukocyte antigen (HLA) class I ligands have evolved as checkpoints to ensure self-tolerance of natural killer cells. Both KIR and HLA genetic profiles are potential biomarkers of immunotherapy outcome. Clin Cancer Res; 24(1); 3-5. ©2017 AACRSee related article by Erbe et al., p. 189.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Biomarkers
  • Child
  • Genotype*
  • HLA-C Antigens / genetics
  • Humans
  • Immunotherapy
  • Killer Cells, Natural / immunology
  • Ligands
  • Neuroblastoma*
  • Receptors, KIR / genetics

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • HLA-C Antigens
  • Ligands
  • Receptors, KIR
  • dinutuximab